esi_2006--Cecchelli_2

68
OVERVIEW OF THE BLOOD-BRAIN BARRIER AND ITS PROPERTIES Laboratoire de Physiopathologie de la Barrière Hémato-Encéphalique EA 2465, IMPRT: IFR 114 Faculté des Sciences Jean Perrin Cellial technologies 62307 Lens- FRANCE Pr Romeo CECCHELLI The Cerebral Vasculature and Neuroimaging in CNS Drug Dicovery And Development: Physiology,Pathology and Methodology Astrazeneca june 2006

description

anes

Transcript of esi_2006--Cecchelli_2

  • OVERVIEW OF THE BLOOD-BRAIN BARRIERAND ITS PROPERTIES

    Laboratoire de Physiopathologie de laBarrire Hmato-Encphalique

    EA 2465, IMPRT: IFR 114 Facult des Sciences Jean Perrin

    Cellial technologies62307 Lens- FRANCE

    Pr Romeo CECCHELLI

    The Cerebral Vasculature and Neuroimaging in CNS Drug DicoveryAnd Development: Physiology,Pathology and Methodology

    Astrazeneca june 2006

  • Goldmann 1913Ehrlich 1885

  • Peptide Drug Delivery to the Brain

    William M. Pardridge 1991

  • The classical view of the BBBformulated by this pioneering work wasbased on evidence that blood-bornesubstances were excluded from thebrain

    The BBB was located in brain capillariesand considered as a rigid structure

  • The Blood-Brain Barrier Cellular and Molecular Biology

    William M. Pardridge 1993

  • Peptide Drug Delivery to the Brain

    William M. Pardridge 1991

  • Brain capillaries are a complex

    structure

  • The Blood-Brain Barrier Cellular and Molecular Biology

    William M. Pardridge 1993

  • Where is located the barrier?

  • Peptide Drug Delivery to the Brain

    William M. Pardridge 1991

    Brain capillary endothelial cells are the physical components ofthe BBB

  • The Blood-Brain Barrier Cellular and Molecular Biology

    William M. Pardridge 1993

  • The Blood-Brain Barrier Cellular and Molecular Biology

    William M. Pardridge 1993

  • The Blood-Brain Barrier Cellular and Molecular Biology

    William M. Pardridge 1993

  • Brain

    7H6ZO-1AF6

    /Cadherins / Cadherins

    ZO-1

    JAMs

    Adherensjunction

    Tightjunction

    claudins

    occludin

    ZO-1ZO-2

    ZO-1ZO-3

    ZO-1ZO-3

    ZO-2ZO-1

    cingulincingulin

    Actin

    Apical plasma membrane

    Blood BBB : a physical barrier

  • Endothelial Cell Biology

    N. Simionescu and M. Simionescu 1988

    Peripheral capillary

  • Endothelial Cell Biology

    N. Simionescu and M. Simionescu 1988

    Peripheral capillary

  • brain

    blood

    endothelial cell

    BBB: PHYSICAL BARRIER

    tightjunction

    No paracellularpassage

    Low transcellulartransport

  • Blood

    Brain

    Dopamine

    L-DOPA

    L-DOPA

    MAODrug-metabolizing

    enzymes

    P-gp

    BBB : a metabolic barrier

    Degradation

  • CYP 450

    MAO-B

    Glutamyl aminopeptidase

    Endothelial cells

    BBB : A METABOLIC BARRIER

    Pericyte

    UGT-1A6

    GST

    CYP 1A1 (rat)CYP 1B1 (human)CYP 2B1 (rat)

    CYP 2B6 (human)

  • Blood

    Brain

    Specific transport(receptor or transporter)

    fluid-phasetranscytosis

    Transport processes through a cerebralendothelium

    ZO

    ZA

    Paracellularpathway

  • EXHAUSTIVE LIST OF BBB TRANSPORTERS ?

    from Terasaki T 2003

  • Different techniques used to study the BBB

  • 14C/3H sucrose/inulin(to measure cerebro-vascular volume

    3H/14C-labelled drug(to measure BBB permeability)

  • endothelial cells

    glial cells

    brain

    blood

    BBB model

    IN VITRO BBB MODEL

  • TRANSPORTERS AT THE BBB

    OCT?OCTN2

    ATP

    P-gpBCRP

    ORGANIC CATIONSNUTRIENTS

    A, B0,+

    ASC

    Na+

    GLUT 1

    ORGANIC ANIONS

    MCT 1OATP Aoatp 2

    OAT4?

    OAT3

  • DD

    D

    D

    D

  • P-gpP-gp proteinprotein ((ConfocalConfocal) - BBCEC) - BBCEC

    Luminal membrane

    Abluminal membrane

    P-gp OCTN2nuclei

    24m0 5 10 15

    0

    10

    20

    30

    Slides (1 = 0.16m)

    Flu

    ore

    sce

    nce

    inte

    nsity

  • Developing new technology is necessary for progression of the BBB research

    There is no selective inhibitors for distinguishing ABCC subtypes and ABCG2.

    Alternative strategy: siRNA

    siRNA can selectively suppress target transporter(s).

    *

    0

    50

    100

    150

    200

    250

    300

    AB

    CG

    2 m

    RN

    A (

    % o

    f c

    on

    tro

    l)

    siRNA

    E2 (-)

    -G

    2-03 NC

    E2 (+)

    -G

    2-03 NC

    *

    0

    50

    100

    150

    200

    250

    300

    AB

    CB

    1 m

    RN

    A (

    % o

    f c

    on

    tro

    l)

    siRNA

    E2 (-)

    -G

    2-03 NC

    E2 (+)

    -G

    2-03 NC

    0

    50

    100

    150

    200

    250

    300

    AB

    CC

    1 m

    RN

    A (

    % o

    f c

    on

    tro

    l)

    siRNA

    E2 (-)

    -G

    2-03 NC

    E2 (+)

    -G

    2-03 NC

    ABCG2 ABCB1/MDR1 ABCC1/MRP1

    G2-03, siRNA for ABCG2; NC, negative control siRNAHori et al. J. Neurochem. 93:63-71 (2005)

    G2-03 siRNA selectively suppressed the expression of rat ABCG2 in brain capillary

    endothelial cells.

  • Regulation of A in the CNS

    (1) Peripheral and central production

    (2) Rapid receptor-mediated transport of soluble formsacross the BBB

    from blood to brain via RAGE [30]

    (3) Similar transport across the BBB from brain to blood[41,43] via

    LRP [21,45]

    (4) Binding to transport proteins such as apoE, apoJ and

    a2-macroglobulin (a2M), which can influence: Absequestration in

    plasma, brain ISF and CSF; the form of Ab accumulation inbrain

    (i.e. soluble versus fibrillar) [6,46,47]; and/or transportacross the BBB

    and bloodCSF barrier [6,65]

    (5) Degradation, mediated by proteins such asenkephalinase [48],

    insulinase, plasmin, tissue plasminogen activator or matrixmetalloproteinases

    [49], or mediated by astrocytes [50,51] and microglia [66]

    (6) Slow removal via ISFCSF bulk flow [57]

    (7) Oligomerization and aggregation [5,6]

    Brain Ab homeostasis is controlled bynumerous pathways (Berislav,2005):

  • Interaction between t-PA with the blood-brain barrier

  • tPA and the Fibrinolytic System

    Benchenane et al., Trends Neurosci 2004

    PAI-1

    release

    inhibition inhibition

    FDPs

    activationtPA

    tPA

    FibrinFibrin clotclot

    2-APpln

    plnplgtPA

    Breakdown

  • Therapies

    ThrombolysisThrombolysis

    tPAActilyse

  • HoweverHowever, , increasingincreasing evidenceevidence supports supports thethe ideaidea thatthat t-PAt-PA couldcould

    alsoalso potentiatepotentiate strokestroke damage damage

  • Does tPA cross the intact BBB in vivo?

    Collagen IV GFAP

  • Intravenous Injection of Biotinylated Albumin

    Collagen IV

    Biot-albumin

    Albumin remains intravascular

  • tPA

    Albumin

    Collagen IVBiotin Merged

    Intravenous Injection of Biotinylated Albumin or Biotinylated tPA

    tPA crosses the intact BBB in vivo

  • tPA does not affect BBB integrity or permeability

    Luminal

    Abluminal

    tPA

    ?

    tPA crosses the BBB in vitro

    ZO-1ZO-1

    ctrl tPA

    Man

    pe

    10-3

    cm/m

    in (s

    ucr

    ose)

    0

    2

    4

    6

    8

    Ctrl tPA Mannitol

    In vitro model of BBB

    Tight junctionsHigh transendothelial resitivity

    Cecchelli et al., 1999

    Ab

    lum

    inaltP

    A a

    cti

    vit

    y(%

    of lo

    adedt

    PA

    )

    0,0

    1,0

    2,0

    3,0

    4,0

    5,0

    0 20 40 60 80 100 120 140

    time (min)

    Time (min) 15 30 60 120 120

    Abluminal tPA

    Luminal-loadedtPA + + + + - rtPAA

    blu

    min

    altP

    A a

    cti

    vit

    y(%

    of lo

    adedt

    PA

    )

    0,0

    1,0

    2,0

    3,0

    4,0

    5,0

    0 20 40 60 80 100 120 140

    time (min)

    Time (min) 15 30 60 120 120

    Abluminal tPA

    Luminal-loadedtPA + + + + - rtPA

  • Receptor-mediated

    How does tPA cross the BBB ?

    Blood-brain barrier

    Non specific

    Transcellular Paracellular

  • Biot-tPA (green)

    Ab

    lum

    inal

    tPA

    act

    ivit

    y (%

    of c

    ontr

    ol)

    0

    20

    40

    60

    80

    100

    120

    140

    37C 4C

    **

    tPA crosses the BBB by transendothelial pathway

  • tPA

    Ctrl RAP Man

    0

    20

    40

    60

    80

    100

    120

    140

    Ab

    lum

    inal

    tPA

    act

    ivit

    y(%

    of c

    ontr

    ol)

    Control RAP Mannose

    *

    Identification of the receptor involved in the passage of tPA

    tPA crosses the intact BBB by LRP-mediated transcytosis

  • There are a lot a sophiticated receptor-mediated transportsat the BBB.

    Tomorrow, I will presenetd you the cellular mechanisms ofthese transports in physiological conditions and the influence ofthe surrounding cells on these transports

  • TheThe simple observation simple observation thatthat epithelialepithelial but but notnot endothelialendothelialcelscels are able to are able to formform a a high-resistancehigh-resistance andand low-low-permeabilitypermeability barrierbarrier in vitro in vitro sheds light on sheds light on thethe importance importanceofof thethe microenvironnement microenvironnement in in thethe maintenance maintenance ofof thethebarrierbarrier propetiespropeties in vivo in vivo

  • Peptide Drug Delivery to the Brain

    William M. Pardridge 1991

  • Astrocytes

    Endothelial

    cells

  • Statistical study of 2D-PAGE area from BCECs

    Co-culture

    Solo-culture

    Important variation : overexpressed in co-culture

    No statistical significant variation

  • P-gp detection by Western Blot analysis

    Isol

    ated

    capi

    llarie

    sBB

    CE in

    cocu

    lture

    BBCE

    in s

    olo

    cultu

    re

    140

    205

    kDa

  • MRP1?

    MRP4

    MRP5

    MRP1?

    MRP4

    MRP5MRP6

    MRP1MRP4

    MRP5MRP6

    MRP6

    P-gp

  • The definition of the BBB has shift today to amore integrated concept that takes into acount

    not only the bidirectionality of the exchangeprocess, but also the discovery that besides theendothelium additional components (astrocytes,neurons) constitute integral parts of the barrierphysiology

  • Working forthe BBB

  • Rippe et al., 2002

    Introduction

    HOW TO CROSS A CONTINUOUS CAPILLARY?

    HOW TO REACH THE BRAIN?

    1. Interendothelial clefts

    1

    2. Transendothelial channel

    2

    3.Transcytosis

    3

    1. Not between cells because of tight junctions

    2. Not by transendothelial channel because of its lack

    3 & 4. By transcellular processes

    4

    4.Transporters

  • Histochemichal detection of -GT in braincapillaries endothelial cells

  • P-gpP-gp proteinprotein ((ConfocalConfocal) - BBCEC) - BBCEC

    Luminal membrane

    Abluminal membrane

    P-gp OCTN2nuclei

    24m0 5 10 15

    0

    10

    20

    30

    Slides (1 = 0.16m)

    Flu

    ore

    sce

    nce

    inte

    nsity

  • CEREBRAL ENDOTHELIUM : METABOLIC AND TRANSPORT BARRIERS

    Na+water

    water

    Na+

    ATPaseK+

    Na+

    Na+

    Glutamate

    Glycine

    Leucine

    Glucose

    P-glycoprotein

    Alcaline PhosphataseGamma-GT

    L-DOPAL-DOPA

    DopamineDopamine

    DCCA

    MAO-B

    DOPAC

    L-DOPA

  • cerebral

    capillary

    Brainparenchyma

    cells

    endothelial cellsendothelial cells

    BBB CEREBRAL VICINITYIntroduction

    Astrocytes

    Pericytes

  • 010

    20

    30

    40

    0 15 30 60

    Time (min)

    Ctrl

    tPA

    Act

    ivit

    y in

    the

    ablu

    min

    al s

    ide

    (% o

    f tP

    A lo

    aded

    in t

    he lu

    min

    al s

    ide)

    Control

    OGDBiot-tPA (red)

    Luminal

    Abluminal

    tPA

    ?

    OGD 4h

    15 30 6015 30 60

    Ctrl OGD

    Abluminal tPA

    Time (min) 15 30 6015 30 660

    Ctrl OGD

    Abluminal tPA

    Time (min)

    OGD****

    OGD potentiates the passage of tPA